Idenix Pharmaceuticals, Inc. Reports Sustained Virologic Response Rate (SVR4) For Phase 2 All-Oral Combination Study Of Samatasvir (IDX719), A Potent, Pan-Genotypic HCV NS5A Inhibitor, And Simeprevir
Published: Jan 13, 2014
CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from the Company's ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (IDX719), Idenix's once-daily pan-genotypic NS5A inhibitor, and simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, plus ribavirin. The combination regimen was well-tolerated in the study. In the treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients receiving 50 mg of samatasvir and 150 mg of simeprevir plus ribavirin, 85 percent (n=17/20) remained undetectable for HCV RNA four weeks after completing therapy (SVR4). The 50 mg dose of samatasvir is the selected dose in the ongoing 3-DAA HELIX-2 clinical trial. The HELIX-1 study results are expected to be presented at a scientific meeting in 2014.
Help employers find you! Check out all the jobs and post your resume.